Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- First Posted Date
- 2015-12-08
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- University of Arizona
- Registration Number
- NCT02623920
- Locations
- 🇺🇸
Arizona Cancer Center at UMC North, Tucson, Arizona, United States
A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2015-11-04
- Last Posted Date
- 2021-05-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 91
- Registration Number
- NCT02596971
- Locations
- 🇦🇺
Concord Repatriation General Hospital; Haematology, Sydney, New South Wales, Australia
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Oncology Associates of Oregon, P.C.; Willamette Valley Cancer Institute, Springfield, Oregon, United States
Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for CD30 Positive Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-01
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Seagen Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT02594163
- Locations
- 🇺🇸
Good Samaritan Hospital, Torrance, California, United States
🇺🇸Saint Francis Cancer Treatment Center, Grand Island, Nebraska, United States
🇵🇱Uniwersyteckie Centrum Kliniczne, Gdańsk, Poland
A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
- First Posted Date
- 2015-10-15
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- SecuraBio
- Registration Number
- NCT02576275
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
- Conditions
- Interventions
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- Fondazione Italiana Linfomi - ETS
- Target Recruit Count
- 43
- Registration Number
- NCT02499627
- Locations
- 🇮🇹
Spedali Civili, Brescia, BS, Italy
🇮🇹AOU Città della Salute e della Scienza, Torino, TO, Italy
🇮🇹IRCCS Fondazione Pascale, Napoli, Italy
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
- Conditions
- Interventions
- First Posted Date
- 2015-05-15
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 48
- Registration Number
- NCT02445131
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Optimising Renal Outcome in Myeloma Renal Failure
- Conditions
- Interventions
- First Posted Date
- 2015-04-23
- Last Posted Date
- 2022-01-27
- Lead Sponsor
- Oxford University Hospitals NHS Trust
- Target Recruit Count
- 31
- Registration Number
- NCT02424851
- Locations
- 🇬🇧
Kent & Canterbury Hospital, Canterbury, United Kingdom
🇬🇧Royal Liverpool Hospital, Liverpool, United Kingdom
🇬🇧Heartlands Hospitals, Birmingham, United Kingdom
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 2
- Registration Number
- NCT02420210
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Bendamustine Study in Classical Hodgkin Lymphoma Patients Over 60 Treated by Prednisone, Vinblastine and Doxorubicin
- Conditions
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 90
- Registration Number
- NCT02414568
- Locations
- 🇫🇷
CHR de Metz-Thionville - Hôpital de Mercy, Metz, France
🇫🇷Hôpital de la Pitié-Salpêtrière, Paris, France
🇫🇷CHRU de Nîmes, Nîmes, France
Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)
- Conditions
- Interventions
- First Posted Date
- 2015-03-27
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02401503
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.